Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: Methods, systems, and apparatus, including medium-encoded computer program products, for computer aided design of physical structures using data format conversion (e.g., of output(s) from generative design processes) and user interface techniques that facilitate the production of 3D models of physical structures that are readily usable with 2.5-axis subtractive manufacturing, include: modifying smooth curves, which have been fit to contours representing discrete height layers of an object, to facilitate the 2.5-axis subtractive manufacturing; preparing an editable model of the object using a parametric feature history, which includes a sketch feature, to combine extruded versions of the smooth curves to form a 3D model of the object in a boundary representation format; reshaping a subset of the smooth curves responsive to user input with respect to the sketch feature; and replaying the parametric feature history to reconstruct the 3D model of the object, as changed by the user input.

Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: Systems and methods for differential document analysis and storage are provided. Specifically, the system can be configured to perform one or more differential analyses on a set of documents to detect and measure changes in language across entire sets of documents of a similar type, as well as changes in language in the specific objects (e.g., document sections, paragraphs, clauses) of the documents. The system comprises three primary components: document parsing, textual near-duplicate detection, and morphological analysis. The document parsing component breaks documents down into objects and creates indexes for each full document and components of the document. These indexes enable documents and objects to be compared for similarity using the near-duplicate detection component, which implements various similarity analysis algorithms. The morphological analyses component is configured to search the documents for particular language or sections and compare documents in which the searched language is present.

Abstract: The disclosed technology includes low flush toilet systems and methods of using low flush toilet systems. In one implementation, a low flush toilet system includes a first (or passive) tank, the first tank configured to preload a toilet rim, and a second (or pressurized) tank, the second tank including an internal air bladder, the internal air bladder configured to compress when exposed to water pressure from a supply line and configured to expand when a flush valve releases pushing water out of the second tank at a high flow rate and into a toilet for flushing. In some implementations, water flows from the pressurized tank at approximately 0.7-1.0 gallons per flush.

Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: Embodiments relate to systems, methods and devices for delivering a drug or other therapy to a patient with an ambulatory infusion pump configured to provide a series of tolerance-building steps leading up to a plateau delivery rate. The plateau delivery rate is maintained until the prescribed amount of drug or therapy fluid is delivered to the patient. Embodiments of the invention include providing the patient or other user with a mechanism to decrease, or step down, the therapy delivery rate if a tolerance was not achieved at a lower rate, and providing notifications prior to a step up in a dosage delivery rate.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

Abstract: A cover device may include a body with an inner surface and an outer surface, each of the inner surface and the outer surface extending from a first end face of the body to a second end face of the body. The inner surface may define a channel extending through the body from the first end face to the second end face. The outer surface may define a plurality of grooves extending from the first end face to the second end face. Each of the body, the inner surface, and the outer surface may be configured to elastically deform relative to at least an axis of the channel.

Abstract: Embodiments relate to systems, methods and devices for delivering a drug or other therapy to a patient with an ambulatory infusion pump configured to provide a series of tolerance-building steps leading up to a plateau delivery rate. The plateau delivery rate is maintained until the prescribed amount of drug or therapy fluid is delivered to the patient. Embodiments of the invention include providing the patient or other user with a mechanism to decrease, or step down, the therapy delivery rate if a tolerance was not achieved at a lower rate, and providing notifications prior to a step up in a dosage delivery rate.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: The Evaporative Cooler Wind Deflector reduces air flow variations of the pads of a rectangular Evaporative Cooler due to Wind. The Evaporative Cooler cools the air by pulling the air through wetted media. In a typical evaporative cooler the wetted media or “pads” are located on the three or four sides of the cooler. In windy conditions the pads on the windward side will have more airflow due to greater pressure. The Evaporative Cooler Wind Deflector will minimize variations in air flow between the pads. It will also minimize water droplets splashing or blowing from the pads and causing roof discoloration or damage.

Abstract: The disclosed technology includes low flush toilet systems and methods of using low flush toilet systems. In one implementation, a low flush toilet system includes a first (or passive) tank, the first tank configured to preload a toilet rim, and a second (or pressurized) tank, the second tank including an internal air bladder, the internal air bladder configured to compress when exposed to water pressure from a supply line and configured to expand when a flush valve releases pushing water out of the second tank at a high flow rate and into a toilet for flushing. In some implementations, water flows from the pressurized tank at approximately 0.7-1.0 gallons per flush.

Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.